癌症诊断人工智慧市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球癌症诊断人工智慧市场价值为 3.31 亿美元，预计到 2034 年将以 23.7% 的复合年增长率增长，达到 28 亿美元，这得益于精准诊断需求的不断增长和全球癌症发病率的上升。人工智慧与肿瘤学的结合正在彻底改变临床医生检测和解释癌症相关资料的方式。人工智慧工具透过将大量临床数据集与医学影像和病理结果整合在一起，增强了诊断工作流程，从而简化了检测并加速了临床决策。非侵入性诊断领域的创新，尤其是在基因组学和分子分析中利用人工智慧的创新，可以实现更快、更准确的筛检，同时支援个人化治疗计划和更好的患者预后。

人工智慧驱动的癌症诊断系统利用机器学习和影像辨识功能，以更高的精度识别异常。这种技术驱动的变革推动了癌症早期检测策略和即时监测的转变，这对于通常无症状进展的癌症至关重要。这些智慧诊断平台透过减少解读错误和提高工作流程效率来支援临床医生。因此，人工智慧的应用正成为下一代癌症治疗的核心，在医疗保健的临床和营运层面带来价值。医院、诊断实验室和研究机构依靠人工智慧平台来提高准确性并缩短週转时间。

2024年，医院领域成为癌症诊断人工智慧市场的主要终端用户，预计到2034年其估值将达到15亿美元。医院在应用尖端人工智慧技术方面始终处于领先地位，这些技术有助于癌症的早期发现和精准诊断。这些机构越来越依赖以人工智慧为基础的工具，例如机器学习演算法、数位病理系统和智慧成像平台，以简化工作流程、减少诊断错误并改善临床决策。人工智慧的整合还能帮助医院管理大量患者资料，同时缩短週转时间，最终提升病患照护效果。

2024年，乳癌领域占了相当大的份额，达到29.4%，这归因于乳癌在全球范围内的广泛发病率，以及对能够在早期发现、更易治疗的恶性肿瘤的技术的迫切需求。人工智慧驱动的诊断解决方案在识别乳房X光、超音波和核磁共振扫描中的细微模式和异常方面尤其有效，而这些模式和异常在常规评估中往往被忽略。将人工智慧融入乳癌筛检不仅可以提高灵敏度和特异性，还可以支援风险分层和个人化治疗计划。由于早期诊断对于减少

2024年，北美癌症诊断人工智慧市场占据41.3%的市场份额，这得益于先进的医疗基础设施、大量的癌症病例以及对人工智慧整合诊断工具日益增长的需求。美国高度重视医疗创新，并积极推动学术机构、医疗新创公司和监管机构之间的合作伙伴关係，加速了人工智慧的普及步伐。深度学习和影像解读技术的快速发展使临床医生能够更早发现肿瘤，并更有效地制定治疗方案，从而降低成本并改善患者预后。

癌症诊断人工智慧产业的主要参与者包括 Tempus、西门子医疗、EarlySign、Vuno、Paige AI、Flatiron、微软、Cancer Center.ai、SkinVision、GE Healthcare、Kheiron Medical Technologies、Nanox Imaging、Path AI 和 Therapixel。为了巩固其在全球癌症诊断人工智慧市场的市场地位，公司正专注于策略合作、软体创新和监管许可。在美国和北美市场，许多参与者投资与医院和生物技术公司的合作，以使用真实世界的临床资料来完善人工智慧模型。主要公司也透过本地化解决方案和参与特定地区的临床试验来扩大其在欧洲和亚太地区的业务。此外，成像演算法和基于云端的诊断平台的持续升级正在帮助供应商在全球范围内扩展其产品/服务，同时满足不断变化的临床需求。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 全球癌症发生率上升
    • 人工智慧技术和成像系统的进步
    • 人工智慧与医疗IT系统的整合
  • 产业陷阱与挑战
    • 实施和营运成本高
    • 对资料隐私和安全的担忧
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对产业的影响
    • 需求面影响（售价）
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 未来市场趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按组成部分，2021-2034

• 主要趋势
• 软体解决方案
• 硬体
• 服务

第六章：市场估计与预测：按癌症类型，2021-2034 年

• 主要趋势
• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 其他癌症类型

第七章：市场估计与预测：依最终用途，2021-2034

• 主要趋势
• 医院
• 诊断实验室
• 其他最终用途

第八章：市场估计与预测：按地区，2021-2034

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Cancer Center.ai
• EarlySign
• Flatiron
• GE Healthcare
• Kheiron Medical Technologies
• Microsoft
• Nanox Imaging
• Paige AI
• Path AI
• Siemens Healthineers
• SkinVision
• Tempus
• Therapixel
• Vuno

The Global Artificial Intelligence in Cancer Diagnostics Market was valued at USD 331 million in 2024 and is estimated to grow at a CAGR of 23.7% to reach USD 2.8 billion by 2034, driven by increasing demand for precision diagnostics and the rising incidence of cancer worldwide. The integration of artificial intelligence into oncology is revolutionizing the way clinicians detect and interpret cancer-related data. AI tools enhance diagnostic workflows by consolidating vast clinical datasets with medical imaging and pathology results, which streamlines detection and accelerates clinical decision-making. Innovations in non-invasive diagnostics, especially those leveraging AI in genomics and molecular profiling, enable faster, more accurate screening while supporting personalized treatment planning and better patient outcomes.

AI-powered cancer diagnostic systems utilize machine learning and image recognition capabilities to identify abnormalities with higher precision. This tech-driven transformation fosters a shift toward early detection strategies and real-time monitoring essential for cancers that typically progress without symptoms. These smart diagnostic platforms support clinicians by reducing interpretation errors and boosting workflow efficiency. As a result, the implementation of AI is becoming central to next-generation cancer care, bringing value across both clinical and operational dimensions in healthcare. Hospitals, diagnostics labs, and research institutions rely on AI platforms to improve accuracy and reduce turnaround time.

In 2024, the hospital segment emerged as the leading end user in the artificial intelligence in cancer diagnostics market and is projected to reach a valuation of USD 1.5 billion by 2034. Hospitals remain at the forefront of adopting cutting-edge AI technologies that assist in the early detection and precise cancer diagnosis. These facilities increasingly rely on AI-based tools such as machine learning algorithms, digital pathology systems, and intelligent imaging platforms to streamline workflows, reduce diagnostic errors, and improve clinical decision-making. Integration of AI also helps hospitals manage large volumes of patient data while enabling faster turnaround times, ultimately enhancing patient care outcomes.

The breast cancer segment held a substantial portion of 29.4% share in 2024, attributed to the widespread incidence of breast cancer globally and the pressing demand for technologies that can detect malignancies at an early, more treatable stage. AI-powered diagnostic solutions are especially impactful in identifying subtle patterns and anomalies in mammograms, ultrasound, and MRI scans, which often go unnoticed during conventional assessments. Integrating AI in breast cancer screening not only enhances sensitivity and specificity but also supports risk stratification and personalized treatment planning. As early diagnosis remains critical in reducing

North America Artificial Intelligence in Cancer Diagnostics Market held 41.3% share in 2024, shaped by advanced healthcare infrastructure, a high volume of cancer cases, and growing demand for AI-integrated diagnostic tools. The country's strong emphasis on medical innovation and collaborative partnerships among academic institutions, healthcare startups, and regulatory agencies has accelerated the pace of AI adoption. Rapid advances in deep learning and imaging interpretation enable clinicians to detect tumors earlier and tailor treatments more effectively, reducing costs and improving patient prognosis.

Major players operating in the artificial intelligence in cancer diagnostics industry include Tempus, Siemens Healthineers, EarlySign, Vuno, Paige AI, Flatiron, Microsoft, Cancer Center.ai, SkinVision, GE Healthcare, Kheiron Medical Technologies, Nanox Imaging, Path AI, and Therapixel.To strengthen their market position in the Global Artificial Intelligence in Cancer Diagnostics Market, companies are focusing on strategic collaborations, software innovation, and regulatory clearances. In the US and North America markets, many players invest in partnerships with hospitals and biotech firms to refine AI models using real-world clinical data. Key companies are also expanding their presence in Europe and Asia Pacific by localizing solutions and engaging in region-specific clinical trials. Furthermore, continuous upgrades in imaging algorithms and cloud-based diagnostic platforms are helping providers scale their offerings globally while addressing evolving clinical demands.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising cancer incidence globally
    • 3.2.1.2 Advancements in AI technologies and imaging systems
    • 3.2.1.3 Integration of AI with healthcare IT systems
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High implementation and operational costs
    • 3.2.2.2 Concerns over data privacy and security
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on the Industry
    • 3.5.1.1 Demand-side impact (selling price)
      • 3.5.1.1.1 Market share dynamics
      • 3.5.1.1.2 Consumer response patterns
  • 3.5.2 Key companies impacted
  • 3.5.3 Strategic industry responses
    • 3.5.3.1 Pricing and product strategies
    • 3.5.3.2 Policy engagement
  • 3.5.4 Outlook and future considerations
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Component, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Software solutions
• 5.3 Hardware
• 5.4 Services

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021-2034 ($ Mn)

• 6.1 Key trends
• 6.2 Breast cancer
• 6.3 Lung cancer
• 6.4 Colorectal cancer
• 6.5 Prostate cancer
• 6.6 Other cancer types

Chapter 7 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Cancer Center.ai
• 9.2 EarlySign
• 9.3 Flatiron
• 9.4 GE Healthcare
• 9.5 Kheiron Medical Technologies
• 9.6 Microsoft
• 9.7 Nanox Imaging
• 9.8 Paige AI
• 9.9 Path AI
• 9.10 Siemens Healthineers
• 9.11 SkinVision
• 9.12 Tempus
• 9.13 Therapixel
• 9.14 Vuno